Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.

Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I; Parkinson Study Group DATATOP and PRECEPT investigators.

Mov Disord. 2009 Dec 15;24(16):2370-8. doi: 10.1002/mds.22828.

PMID:
19908310
2.
3.

Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.

Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE; Parkinson Study Group DATATOP and PRECEPT investigators.

Mov Disord. 2011 Mar;26(4):608-13. doi: 10.1002/mds.23581. Epub 2011 Feb 1.

PMID:
21287602
4.
6.

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.

Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A; Parkinson Study Group.

Ann Neurol. 2002 May;51(5):604-12.

PMID:
12112107
9.
10.
12.

Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.

Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE; Parkinson Study Group DATATOP Investigators.

Mov Disord. 2008 Apr 15;23(5):653-9; quiz 776.

PMID:
18076084
13.

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A; Parkinson Study Group.

Arch Neurol. 2004 Jul;61(7):1044-53. Erratum in: Arch Neurol. 2005 Mar;62(3):430.

PMID:
15262734
14.
16.

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.

Parkinson Study Group CALM Cohort Investigators.

Arch Neurol. 2009 May;66(5):563-70. doi: 10.1001/archneur.66.1.nct90001.

PMID:
19433655
17.

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.

Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F.

Mov Disord. 1998 Jan;13(1):46-51.

PMID:
9452325
18.

The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group.

Kieburtz K, McDermott M, Como P, Growdon J, Brady J, Carter J, Huber S, Kanigan B, Landow E, Rudolph A, et al.

Neurology. 1994 Sep;44(9):1756-9.

PMID:
7936311
19.

Delayed development of symptomatic improvement by (--)-deprenyl in Parkinson's disease.

Mally J, Kovacs AB, Stone TW.

J Neurol Sci. 1995 Dec;134(1-2):143-5.

PMID:
8747857
20.

Effects of selegiline (deprenyl) on cognition in early Parkinson's disease.

Dalrymple-Alford JC, Jamieson CF, Donaldson IM.

Clin Neuropharmacol. 1995 Aug;18(4):348-59.

PMID:
8665548

Supplemental Content

Support Center